greeksoup/ stocks
Stocks / India / ZYDUSLIFE / Documents

Zydus Lifesciences Ltd. documents

101 documents on Zydus Lifesciences Ltd.: 12 annual reports, 6 investor presentations, 22 analyst and investor calls: notices, recordings, transcripts, 60 press releases, 1 credit rating letters. Annual reports from the exchange's archive; the rest from twelve months of Regulation 30 announcements, in the exchange's own categories, each linked to the PDF the company filed.

Annual reports

FiledDocumentOpenWhere
10 July 2026Annual report 2025 to 2026 (New)PDF
16 July 2025Annual report 2024 to 2025 (New)PDF
11 July 2024Annual report 2023 to 2024 (-)PDF
14 July 2023Annual report 2022 to 2023 (-)PDF
Annual report 2021 to 2022 (-)PDF
Annual report 2020 to 2021 (-)PDF
Annual report 2019 to 2020 (-)PDF
Annual report 2018 to 2019 (-)PDF
14 August 2018Annual report 2017 to 2018 (-)PDF
17 August 2017Annual report 2016 to 2017 (-)PDF
5 August 2016Annual report 2015 to 2016 (-)PDF
16 July 2015Annual report 2014 to 2015 (-)PDF

Investor presentations

FiledDocumentOpenWhere
23 August 2026Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF
11 August 2026Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF
19 May 2026Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF
9 February 2026Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF
25 November 2025Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF
6 November 2025Zydus Lifesciences Limited has informed the Exchange about Investor PresentationPDF

Analyst and investor calls: notices, recordings, transcripts

FiledDocumentOpenWhere
11 September 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
18 August 2026Zydus Lifesciences Limited has informed the Exchange about TranscriptPDF
17 August 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
12 August 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
11 August 2026Zydus Lifesciences Limited has informed the Exchange about Link of RecordingPDF
10 August 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
4 August 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
4 August 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
30 July 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
24 May 2026Zydus Lifesciences Limited has informed the Exchange about TranscriptPDF
23 May 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
21 May 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
19 May 2026Zydus Lifesciences Limited has informed the Exchange about Link of RecordingPDF
13 May 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
18 February 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
15 February 2026Zydus Lifesciences Limited has informed the Exchange about TranscriptPDF
10 February 2026Zydus Lifesciences Limited has informed the Exchange about Link of RecordingPDF
4 February 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
30 January 2026Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF
13 November 2025Zydus Lifesciences Limited has informed the Exchange about TranscriptPDF
6 November 2025Zydus Lifesciences Limited has informed the Exchange about Link of RecordingPDF
29 October 2025Zydus Lifesciences Limited has informed the Exchange about Schedule of meetPDF

Press releases

FiledDocumentOpenWhere
31 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH".PDF
21 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity".PDF
11 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency- Associated Lung Disease (AATD-LD)".PDF
11 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 11, 2026, titled "Press Release".PDF
10 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 10, 2026, titled "Zydus launches REVAHALE , India s first once-daily nebulised LAMA for COPD".PDF
4 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 04, 2026, titled "Zydus announces Final Approval from the USFDA for Indocyanine Green for Injection with 180-Days CGT exclusivity".PDF
1 August 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated August 01, 2026, titled "Zydus receives EIR from the USFDA for its injectable facility with VAI classification".PDF
23 July 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 23, 2026, titled "Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR".PDF
3 July 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 03, 2026, titled "Zydus signs MoU with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection test (MCD) in India".PDF
16 June 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 16, 2026, titled "Zydus announces the successful completion of acquisition of Assertio Holdings".PDF
28 May 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Zydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDA".PDF
19 May 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release".PDF
6 May 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated May 06, 2026, titled "USFDA inspection concludes at Zydus' Biologics Injectable plant, Ahmedabad".PDF
25 April 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2026, titled "Zydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate".PDF
16 April 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 16, 2026, titled "Zydus receives EIR for oncology injectable manufacturing facility in SEZ1, Ahmedabad".PDF
8 April 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 08, 2026, titled "Zydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg".PDF
21 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Zydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in India".PDF
19 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 19, 2026, titled "Zydus launches Aerolife Mini , to simplify inhaler use for asthma and COPD patients".PDF
18 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 18, 2026, titled "Zydus and Torrent Pharma sign licensing agreement to co-market innovative Semaglutide Injection in India".PDF
17 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 17, 2026, titled "Zydus and Lupin sign licensing agreement for co-marketing innovative Semaglutide Injection in India".PDF
16 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 16, 2026, titled "Sentynl Therapeutics Enters into Agreement with PRG S&T to License Molecule for Hutchinson-Gilford Progeria Syndrome".PDF
14 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 14, 2026, titled "Zydus new drug discovery, Desidustat licensed to China Medical System Holdings receives approval from NMPA of China".PDF
13 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 13, 2026, titled "Zydus receives final approval from USFDA for Cevimeline Hydrochloride Capsules 30mg".PDF
12 March 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 12, 2026, titled "Zydus expands companion diagnostics portfolio with the launch of AI-powered Continuous Glucose Monitor DiasensTM and GlucoLiveTM".PDF
28 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Zydus receives final approvals from USFDA for Ivermectin Tablets USP, 3 mg and Dapsone Tablets USP, 25 mg and 100 mg".PDF
27 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 27, 2026, titled "Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing".PDF
25 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 25, 2026, titled "Zydus plans to launch innovative Semaglutide Injection in India on Day 1 of patent expiry, expanding patient access to GLP-1 therapy".PDF
19 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Closure of USFDAinspection at Zydus Injectable plant at Ahmedabad".PDF
19 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 19, 2026, titled "Zydus launches biosimilar Aflibercept 2 mg ANYRA for advancing ophthalmic care ".PDF
18 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 18, 2026, titled "Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg".PDF
17 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 17, 2026, titled "Zydus launches PEPAIR, a first in India, affordable, drug-free, handheld device for better respiratory health".PDF
14 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 14, 2026, titled "Zydus receives final approval from USFDA for Ammonium Lactate Cream, 12%".PDF
9 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 09, 2026, titled "Press Release".PDF
6 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease".PDF
4 February 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 04, 2026, titled "Zydus receives tentative approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mg".PDF
23 January 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 23, 2026, titled "Outcome of USFDA inspection".PDF
22 January 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 22, 2026, titled "Zydus launches the world s first biosimilar of Nivolumab, Tishtha , in India to treat multiple cancers".PDF
15 January 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg".PDF
13 January 2026Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 13, 2026, titled "Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)".PDF
23 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".PDF
19 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 19, 2025, titled "Zydus Lifesciences Limited signs an exclusive agreement with Myriad Genetics of US to launch cancer-risk assessment diagnostic tests in India".PDF
15 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 15, 2025, titled "Sentynl Therapeutics Announces FDA Acceptance of CUTX-101 NDA Resubmission".PDF
10 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 10, 2025, titled "Zydus launches biosimilar Denosumab 120 mg SC protecting bone health in cancer patients".PDF
9 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 09, 2025, titled "Zydus and Formycon enter into an Exclusive Partnership for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab), in US and Canada".PDF
4 December 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Zydus receives EIR for the injectable facility located at Jarod".PDF
27 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 27, 2025, titled "Zydus receives tentative approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg".PDF
26 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 26, 2025, titled "Zydus and RK Pharma enter into an exclusive licensing and commercialization agreement for a novel 505(b)(2) product of supportive oncology treatment for the USA market.".PDF
25 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 25, 2025, titled "Zydus receives final approval from USFDA for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg".PDF
14 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 14, 2025, titled "Zydus receives final approval from USFDA for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial".PDF
13 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Closure of USFDA inspection at Zydus oncology injectable manufacturing facility in SEZ1, Ahmedabad".PDF
13 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Revised press release".PDF
13 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus receives final approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg".PDF
13 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Zydus Amplitude receives CE mark for its robotic surgical system Andy .PDF
11 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Zydus receives approval from China s NMPA for Venlafaxine Extended-Release Capsules, 75 mg and 150 mg".PDF
7 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 07, 2025, titled "Zydus receives tentative approval from USFDA for Olaparib Tablets, 100 mg and 150 mg".PDF
6 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Financial Performance for Q2 & H1 FY26".PDF
6 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 06, 2025, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of beta-thalassemia".PDF
5 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 05, 2025, titled "Zydus receives EIR for SEZ II manufacturing facility, Ahmedabad".PDF
4 November 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated November 04, 2025, titled "Zydus receives tentative approval from USFDA for Budesonide delayed release capsules, 4 mg".PDF
29 October 2025Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 29, 2025, titled "Zydus receives EIR for the Baddi manufacturing facility".PDF

Credit rating letters

FiledDocumentOpenWhere
11 September 2026Zydus Lifesciences Limited has informed the Exchange about Credit RatingPDF

Source

Corporate announcements on nseindia.com and the annual reports archive.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install